THE EFFECT OF COMBINATION THERAPY WITH PD FERON-B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C: A QUASI-EXPERIMENTAL STUDY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ALAVIAN S.M.; KABIR A.; HAJIBEYGI B.; DOROUDI T.; SABER H.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Physiology and Pharmacology Year:2004 | Volume:8 | Issue:1 Page(s): 71-82

Download Full-Text

Persian Verion

View:

3,622

Download:

Cites:

Information Journal Paper

Title

THE EFFECT OF COMBINATION THERAPY WITH PD FERON-B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C: A QUASI-EXPERIMENTAL STUDY

Author(s)

Keywords

PD FERONQ4

RIBAVIRINQ4

INTERFERONQ3

HEPATITIS CQ3

Abstract

Approximately 200 million people worldwide and about 200,000 people in Iran are infected with HCY virus. HEPATITIS C is one of the leading causes of liver failure and cancer and is the single most common indication for liver transplantation.A quasi-experimental study was conducted on 54 patients with chronic HEPATITIS C. The patients were treated with a combination of PD FERON-B (3 MID, three times per week) plus RIBAVIRIN (600-1000 mg per day) for one year. CBC and platelet counts and liver and thyroid function tests were performed at 3rd, 6th, 9th and 12th months. In addition, HCY-RNA was measured using RT-PCR method at 3rd and 12th months. For statistical analysis, t test, chi-square, repeated measures ANOYA and regression analysis tests were used.The results showed that the therapy continued in 52 patients (96.3%) and 47 (90.4%) out of them were male. In addition, the reduction in liver enzymes was significant (p<0.001).HCY-RNA was negative in 77.8% of the patients at the end of 3rd month and in 85.4% at the end of treatment (p>0.001). Meanwhile, in 18.9% of the patients, no complication was noted and in the other 81.9%, there was no serious side effect. Finally, valuable models for prediction of HCY-RNA and the level of aminotransferases at the end of therapy were obtained (P>0.001). Since no serious side effect was. observed during therapy period and considering its compatibility with other drug regiments, accessibility and cost-effectiveness of PD FERON-B, therefore, this combination therapy can be recommend in patients with chronic HEPATITIS C.

Cites

No record.

References

Cite

APA: Copy

ALAVIAN, S.M., KABIR, A., HAJIBEYGI, B., DOROUDI, T., & SABER, H.R.. (2004). THE EFFECT OF COMBINATION THERAPY WITH PD FERON-B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C: A QUASI-EXPERIMENTAL STUDY. PHYSIOLOGY AND PHARMACOLOGY, 8(1), 71-82. SID. https://sid.ir/paper/75278/en

Vancouver: Copy

ALAVIAN S.M., KABIR A., HAJIBEYGI B., DOROUDI T., SABER H.R.. THE EFFECT OF COMBINATION THERAPY WITH PD FERON-B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C: A QUASI-EXPERIMENTAL STUDY. PHYSIOLOGY AND PHARMACOLOGY[Internet]. 2004;8(1):71-82. Available from: https://sid.ir/paper/75278/en

IEEE: Copy

S.M. ALAVIAN, A. KABIR, B. HAJIBEYGI, T. DOROUDI, and H.R. SABER, “THE EFFECT OF COMBINATION THERAPY WITH PD FERON-B AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C: A QUASI-EXPERIMENTAL STUDY,” PHYSIOLOGY AND PHARMACOLOGY, vol. 8, no. 1, pp. 71–82, 2004, [Online]. Available: https://sid.ir/paper/75278/en

Related Journal Papers